Novo Nordisk Inc Drug Patent Portfolio

Novo Nordisk Inc's Family Patents

Drugs Generating Over $1 Billion in Annual Revenue

Explore the top-performing drugs that dominate the pharmaceutical industry

View List

NCE-1 Patent Expiry in the Next 1 Year

Identify opportunities as new chemical entity (NCE-1) patents approach expiry

View List

Recently Granted Patents in EP

Find the opportunity to file Oppositions

View List

Possible challenges as weight loss medications become available in generic form - Palatinate

12 Feb, 2026

Novo Nordisk's Patent Victory Reduces Threat of Generic Competition, Yet Pricing Concerns Remain - Simply Wall St

12 Feb, 2026

The Trump administration is being encouraged to invoke a federal statute to permit the production of generic GLP-1 medications.

12 Feb, 2026

Pharmaceutical Patent Searches Require Improvement to Keep Pace with Contemporary Innovations

12 Feb, 2026